Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com
Age Associated With Survival, Time to Richter Transformation in AYA Patients With CLL
May 30th 2021Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.
New Treatment Methods Launch a Shift in CRC Treatment
March 13th 2021Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.
PARP Inhibitors Are a Mainstay in Metastatic Breast Cancer
March 8th 2021Olaparib and talazoparib didn't show statistically significant improvements in overall survival compared with chemotherapy in certain patients with metastatic breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control.
CAR T-Cell Therapy Is Active, Safe in ALL
February 28th 2021Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.
Immunotherapy May Highlight Neoadjuvant Treatment's Use in Lung Cancer
January 25th 2021The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.
Immunotherapy Is Promising, Yet Understudied in Myeloid Malignancies
January 18th 2021Survival for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date, according to Amer Zeidan, MD, MHS.
Lung Cancer Advancements Continue, Despite COVID-19
December 3rd 2020The coronavirus disease 2019 (COVID-19) pandemic has become another potential complication for patients with lung cancer, said Mark G. Kris, MD, who added that although the pandemic has disrupted patient care, it has yet to stunt scientific collaboration.
Cemiplimab Is Promising for Metastatic Basal Cell Carcinoma Treatment
November 18th 2020Cemiplimab (Libtayo) demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma (mBCC) after progression on or intolerance to hedgehog inhibitors.
Pediatric Osteosarcoma and Pathogenic TP53 Variants
October 19th 2020TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma, according to findings from the Children’s Oncology Group that were published in JCO Precision Oncology.
Clinical Trials Will Change the Metastatic Pancreatic Cancer Landscape
October 16th 2020Clinical trials should not be viewed as a last resort for patients with metastatic pancreatic cancer, explained Allyson Ocean, MD, who added that even frontline standards of care should be considered after exhausting all available study options.
Immunotherapy Combos in Advanced Nonsquamous NSCLC: What Does the Data Say?
September 29th 2020The paradigm of advanced nonsquamous non–small cell lung cancer (NSCLC) is now one that necessitates discussions regarding the use of combination chemoimmunotherapy, combination immunotherapy, and single-agent immunotherapy, explained Jonathan Dowell, MD.
2020 Brings Exciting Advancements for NSCLC Treatment
July 6th 2020Fam-trastuzumab deruxtecan-nxki (Enhertu) could provide patients with metastatic non–small cell lung cancer (NSCLC) who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy. However, the jury is still out on whether the agent will be pursued as an alternative frontline therapy and in both patient subsets.
Drug Duo Is Promising in Older Patients With Advanced HCC
July 5th 2020The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated comparable clinical activity and safety versus sorafenib (Nexavar) in older and younger patients with previously untreated, unresectable hepatocellular carcinoma (HCC).
Novel Drug Appears Safe and Active for Advanced Solid Tumors
June 3rd 2020The CD71-directed probody-drug conjugate (PDC) of monomethyl auristatin E (MMAE) CX-2029 showed tolerability and antitumor activity in patients with advanced cancer, according to findings from the first-in-human phase 1/2 PROCLAIM-CX-2029 trial (NCT03543813) that were presented during the 2020 ASCO Virtual Scientific Program.